CME/CE
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
316-330 of 1026
Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
CME/CEReal-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
An De Vriese, MD, PhD
Muh Geot Wong, MBBS, PhD
Advances in Managing Neuropsychiatric Symptoms of Alzheimer’s Disease: From Early Detection to Emerging Therapies
CME/CEAdvances in Managing Neuropsychiatric Symptoms of Alzheimer’s Disease: From Early Detection to Emerging Therapies
Marwan Sabbagh, MD, FAAN
Christoph U. Correll, MD
Alireza Atri, MD, PhD
Test Your Skills and Learn From Experts on IL-13 Inhibitors in Moderate to Severe Atopic Dermatitis
CME/CETest Your Skills and Learn From Experts on IL-13 Inhibitors in Moderate to Severe Atopic Dermatitis
Andrew F. Alexis, MD, MPH
Daniel C. Butler, MD
Shawn G. Kwatra, MD
New Insights in the Management of HCM: Exploring the Clinical Spectrum
CME/CE Broadcast ReplayNew Insights in the Management of HCM: Exploring the Clinical Spectrum
Milind Y. Desai, MD, MBA
Iacopo Olivotto, MD
Elena Arbelo, MD, PhD
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
CME/CE Broadcast ReplayCrossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
Prof. Ulrich Laufs
Pam R. Taub, MD, FACC, FASPC
Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
Christie Ballantyne, MD
Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
CME/CEOptimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
John McMurray, MD
Scott Solomon, MD
- advertisement
Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
MinuteCE®Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
James M. Cleary, MD, PhD
Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers
MinuteCE®Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers
James M. Cleary, MD, PhD
Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers
MinuteCE®Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers
James M. Cleary, MD, PhD
James M. Cleary, MD, PhD
Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer
MinuteCE®Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer
James M. Cleary, MD, PhD
Luis Paz-Ares, MD, PhD
Lauren A. Byers, MD
- advertisement
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
MinuteCE®Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
Luis Paz-Ares, MD, PhD
Lauren A. Byers, MD
Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
MinuteCE®Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
Luis Paz-Ares, MD, PhD
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC
MinuteCE®Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC
Lauren A. Byers, MD
